Breast cancer risk have been discussed to be associated with polymorphisms in genes as well as abnormal DNA damage repair function. This study aims to assess the relationship between genes single nucleotide polymorphisms (SNPs) related to DNA damage repair and female breast cancer risk in Chinese population. A case–control study containing 400 patients and 400 healthy controls was conducted. Genotype was identified using the sequence MassARRAY method and expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2) in tumor tissues was analyzed by immunohistochemistry assay. The results revealed that ATR rs13091637 decreased breast cancer risk influenced by ER, PR (CT/TT vs. CC: adjusted odds ratio [OR] = 1.54, 95% confidence interval [CI]: 1.04–2.27, p = 0.032; CT/TT vs. CC: adjusted OR = 1.63, 95%CI: 1.14–2.35, p = 0.008) expression. Stratified analysis revealed that PALB2 rs16940342 increased breast cancer risk in response to menstrual status (AG/GG vs. AA: adjusted OR = 1.72, 95%CI: 1.13–2.62, p = 0.011) and age of menarche (AG/GG vs. AA: adjusted OR = 1.54, 95%CI: 1.03–2.31, p = 0.037), whereas ATM rs611646 and Ku70 rs132793 were associated with reduced breast cancer risk influenced by menarche (GA/AA vs. GG: adjusted OR = 0.50, 95%CI: 0.30–0.95, p = 0.033). In a summary, PALB2 rs16940342, ATR rs13091637, ATM rs611646, and Ku70 rs132793 were associated with breast cancer risk.
Get full access to this article
View all access options for this article.
References
1.
Abd El-FattahAA, SadikNAH, ShakerOG, et al.Single nucleotide polymorphism in SMAD7 and CHI3L1 and colorectal cancer risk. Mediators Inflamm, 2018; 2018:9853192; doi: 10.1155/2018/9853192
2.
AndersonS, BartowBB, SiegalGP, et al.The dynamics of HER2-low expression during breast cancer progression. Breast Cancer Res Treat, 2023; 201(3):437–446; doi: 10.1007/s10549-023-07020-z
3.
Bahreini, Rayzan andRezaei. microRNA-related single-nucleotide polymorphisms and breast cancer. J Cell Physiol, 2021; 236(3):1593–1605; doi: 10.1002/jcp.29966.
4.
BradburyA, HallS, CurtinN, et al.Targeting ATR as cancer therapy: A new era for synthetic lethality and synergistic combinations?. Pharmacol Ther, 2020; 207:107450; doi: 10.1016/j.pharmthera.2019.107450
5.
CecenerG, Guney EskilerG, EgeliU, et al.Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey. Mol Biol Rep, 2016; 43(11):1273–1284; doi: 10.1007/s11033-016-4061-4
6.
ChenP, LiangJ, WangZ, et al.Association of common PALB2 polymorphisms with breast cancer risk: A case-control study. Clin Cancer Res, 2008; 14(18):5931–5937; doi: 10.1158/1078-0432.Ccr-08-0429
7.
Cintolo-GonzalezJA, BraunD, BlackfordAL, et al.Breast cancer risk models: A comprehensive overview of existing models, validation, and clinical applications. Breast Cancer Res Treat, 2017; 164(2):263–284; doi: 10.1007/s10549-017-4247-z
8.
Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol, 2012; 13(11):1141–1151; doi: 10.1016/s1470-2045(12)70425-4
9.
DaraeiA, IzadiP, KhorasaniG, et al.Methylation of progesterone receptor isoform A promoter in normal breast tissue: An epigenetic link between early age at menarche and risk of breast cancer?. J Cell Biochem, 2019; 120(8):12393–12401; doi: 10.1002/jcb.28505
10.
DengP, WangZ, ChenJ, et al.RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer. J Clin Invest, 2022; 132(22):e159628; doi: 10.1172/jci159628
11.
Di NardoM, PallottaMM, MusioA. The multifaceted roles of cohesin in cancer. J Exp Clin Cancer Res, 2022; 41(1):96; doi: 10.1186/s13046-022-02321-5
12.
DuijfPHG, NanayakkaraD, NonesK, et al.Mechanisms of genomic instability in breast cancer. Trends Mol Med, 2019; 25(7):595–611; doi: 10.1016/j.molmed.2019.04.004
13.
EigerD, AgostinettoE, Saúde-CondeR, et al.The exciting new field of HER2-low breast cancer treatment. Cancers (Basel), 2021; 13(5):1015; doi: 10.3390/cancers13051015
14.
FadasonT, FarrowS, GokuladhasS, et al.Assigning function to SNPs: Considerations when interpreting genetic variation. Semin Cell Dev Biol, 2022; 121:135–142; doi: 10.1016/j.semcdb.2021.08.008
15.
FanfaniV, CitiL, HarrisAL, et al.The landscape of the heritable cancer genome. Cancer Res, 2021a;81(10):2588–2599; doi: 10.1158/0008-5472.Can-20-3348
16.
FanfaniV, ZatopkovaM, HarrisAL, et al.Dissecting the heritable risk of breast cancer: From statistical methods to susceptibility genes. Semin Cancer Biol, 2021b;72:175–184; doi: 10.1016/j.semcancer.2020.06.001
17.
FooTK, XiaB. BRCA1-dependent and independent recruitment of PALB2-BRCA2-RAD51 in the DNA damage response and cancer. Cancer Res, 2022; 82(18):3191–3197; doi: 10.1158/0008-5472.Can-22-1535
18.
GabrielS, ZiaugraL, TabbaaD. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet, 2009; Chapter 2:Unit 2.12; doi: 10.1002/0471142905.hg0212s60
19.
GailMH. Twenty-five years of breast cancer risk models and their applications. J Natl Cancer Inst, 2015; 107(5):djv042; doi: 10.1093/jnci/djv042
20.
GaoC, ZhuangJ, ZhouC, et al.SNP mutation-related genes in breast cancer for monitoring and prognosis of patients: A study based on the TCGA database. Cancer Med, 2019; 8(5):2303–2312; doi: 10.1002/cam4.2065
21.
GomesBC, SilvaSN, AzevedoAP, et al.The role of common variants of non-homologous end-joining repair genes XRCC4, LIG4 and Ku80 in thyroid cancer risk. Oncol Rep, 2010; 24 (4): 1079–1085
22.
HanL, LeeCK, PangH, et al.Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status. Lung Cancer, 2017; 114:79–89; doi: 10.1016/j.lungcan.2017.10.012
23.
HeW, LuoS, HuangT, et al.The Ku70 -1310C/G promoter polymorphism is associated with breast cancer susceptibility in Chinese Han population. Mol Biol Rep, 2012; 39(1):577–583; doi: 10.1007/s11033-011-0773-7
24.
Henríquez-HernándezLA, ValencianoA, Foro-ArnalotP, et al.Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population. Prostate Cancer Prostatic Dis, 2016; 19(1):28–34; doi: 10.1038/pcan.2015.63
25.
HsuCF, TsengHC, ChiuCF, et al.Association between DNA double strand break gene Ku80 polymorphisms and oral cancer susceptibility. Oral Oncol, 2009; 45(9):789–793; doi: 10.1016/j.oraloncology.2008.12.002
26.
HuangR, ZhouPK. DNA damage repair: Historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct Target Ther, 2021; 6(1):254; doi: 10.1038/s41392-021-00648-7
27.
InagawaT, WenninkT, LebbinkJHG, et al.C-terminal extensions of Ku70 and Ku80 differentially influence DNA end binding properties. Int J Mol Sci, 2020; 21(18):6725; doi: 10.3390/ijms21186725
28.
KottemannMC, SmogorzewskaA. Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature, 2013; 493(7432):356–363; doi: 10.1038/nature11863
29.
KudelovaE, SmolarM, HolubekovaV, et al.Genetic heterogeneity, tumor microenvironment and immunotherapy in triple-negative breast cancer. Int J Mol Sci, 2022; 23(23):14937; doi: 10.3390/ijms232314937
30.
LiCI, MaloneKE, DalingJR, et al.Timing of menarche and first full-term birth in relation to breast cancer risk. Am J Epidemiol, 2008; 167(2):230–239; doi: 10.1093/aje/kwm271
31.
LiJQ, ChenJ, LiuNN, et al.Ku80 gene G-1401T promoter polymorphism and risk of gastric cancer. World J Gastroenterol, 2011; 17(16):2131–2136; doi: 10.3748/wjg.v17.i16.2131
32.
LinWY, BrockIW, ConnleyD, et al.Associations of ATR and CHEK1 single nucleotide polymorphisms with breast cancer. PLoS One, 2013; 8(7):e68578; doi: 10.1371/journal.pone.0068578
33.
LiuY, TobiasDK, SturgeonKM, et al.Physical activity from menarche to first pregnancy and risk of breast cancer. Int J Cancer, 2016; 139(6):1223–1230; doi: 10.1002/ijc.30167
34.
MartiniR, NewmanL, DavisM. Breast cancer disparities in outcomes; unmasking biological determinants associated with racial and genetic diversity. Clin Exp Metastasis, 2022; 39(1):7–14; doi: 10.1007/s10585-021-10087-x
35.
MehmoodA, KayaniMA, AhmedMW, et al.Association between single nucleotide polymorphisms of DNA damage response pathway genes and increased risk in breast cancer. Future Oncol, 2020; 16(26):1977–1995; doi: 10.2217/fon-2020-0086
36.
MishraGD, PandeyaN, DobsonAJ, et al.Early menarche, nulliparity and the risk for premature and early natural menopause. Hum Reprod, 2017; 32(3):679–686; doi: 10.1093/humrep/dew350
37.
NepomucenoTC, CarvalhoMA, RodrigueA, et al.PALB2 variants: Protein domains and cancer susceptibility. Trends Cancer, 2021; 7(3):188–197; doi: 10.1016/j.trecan.2020.10.002
38.
NolanE, LindemanGJ, VisvaderJE. Deciphering breast cancer: From biology to the clinic. Cell, 2023; 186(8):1708–1728; doi: 10.1016/j.cell.2023.01.040
39.
OreskovicE, WheelerEC, MengwasserKE, et al.Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1. Proc Natl Acad Sci U S A, 2022; 119(7):e2120540119; doi: 10.1073/pnas.2120540119
40.
PasaniucB, PriceAL. Dissecting the genetics of complex traits using summary association statistics. Nat Rev Genet, 2017; 18(2):117–127; doi: 10.1038/nrg.2016.142
SehlME, LangerLR, PappJC, et al.Associations between single nucleotide polymorphisms in double-stranded DNA repair pathway genes and familial breast cancer. Clin Cancer Res, 2009; 15(6):2192–2203; doi: 10.1158/1078-0432.Ccr-08-1417
43.
SharafR, MontesionM, HopkinsJF, et al.A pan-cancer landscape of telomeric content shows that RAD21 and HGF alterations are associated with longer telomeres. Genome Med, 2022; 14(1):25; doi: 10.1186/s13073-022-01029-7
44.
ShuX, GuJ, HuangM, et al.Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis, 2018; 39(6):752–757; doi: 10.1093/carcin/bgy021
45.
SiegelRL, MillerKD, FuchsHE, et al.Cancer statistics, 2022. CA Cancer J Clin, 2022; 72(1):7–33; doi: 10.3322/caac.21708
46.
SinghA, SinghN, BeheraD, et al.Role of polymorphic XRCC6 (Ku70)/XRCC7 (DNA-PKcs) genes towards susceptibility and prognosis of lung cancer patients undergoing platinum based doublet chemotherapy. Mol Biol Rep, 2018; 45(3):253–261; doi: 10.1007/s11033-018-4158-z
47.
StracquadanioG, WangX, WallaceMD, et al.The importance of p53 pathway genetics in inherited and somatic cancer genomes. Nat Rev Cancer, 2016; 16(4):251–265; doi: 10.1038/nrc.2016.15
48.
StucciLS, InternòV, TucciM, et al.The ATM gene in breast cancer: Its relevance in clinical Practice. Genes (Basel), 2021; 12(5):727; doi: 10.3390/genes12050727
49.
SudA, KinnersleyB, HoulstonRS. Genome-wide association studies of cancer: Current insights and future perspectives. Nat Rev Cancer, 2017; 17(11):692–704; doi: 10.1038/nrc.2017.82
50.
ThomasRK, BakerAC, DebiasiRM, et al.High-throughput oncogene mutation profiling in human cancer. Nat Genet, 2007; 39(3):347–351; doi: 10.1038/ng1975
51.
ThompsonD, DuedalS, KirnerJ, et al.Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst, 2005; 97(11):813–822; doi: 10.1093/jnci/dji141
52.
TrapaniD, GinsburgO, FadeluT, et al.Global challenges and policy solutions in breast cancer control. Cancer Treat Rev, 2022; 104:102339;doi: 10.1016/j.ctrv.2022.102339
53.
TubbsT, NussenzweigA. Endogenous DNA damage as a source of genomic instability in cancer. Cell, 2017; 168(4):644–656; doi: 10.1016/j.cell.2017.01.002
54.
VuorinenSI, OkolicsanyiRK, GyimesiM, et al.SDC4-rs1981429 and ATM-rs228590 may provide early biomarkers of breast cancer risk. J Cancer Res Clin Oncol, 2023; 149(8):4563–4578; doi: 10.1007/s00432-022-04236-2
55.
WangMH, CordellHJ, Van SteenK. Statistical methods for genome-wide association studies. Semin Cancer Biol, 2019; 55:53–60; doi: 10.1016/j.semcancer.2018.04.008
56.
WangX, WangC, GuanJ, et al.Progress of breast cancer basic research in China. Int J Biol Sci, 2021; 17(8):2069–2079; doi: 10.7150/ijbs.60631
57.
WillemsP, De RuyckK, Van den BroeckeR, et al.A polymorphism in the promoter region of Ku70/XRCC6, associated with breast cancer risk and oestrogen exposure. J Cancer Res Clin Oncol, 2009; 135(9):1159–1168; doi: 10.1007/s00432-009-0556-x
58.
WongMW, NordforsC, MossmanD, et al.BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat, 2011; 127(3):853–859; doi: 10.1007/s10549-011-1443-0
59.
WuS, ZhouJ, ZhangK, et al.Molecular mechanisms of PALB2 function and its role in breast cancer management. Front Oncol, 2020; 10:301; doi: 10.3389/fonc.2020.00301
60.
WuY, DongX, WangY, et al.Association between rs120963, rs152451, rs249935, rs447529, rs8053188, and rs16940342 polymorphisms in the PALB2 gene and breast cancer susceptibility: A meta-analysis. Oncol Res Treat, 2018; 41(12):780–786; doi: 10.1159/000492827
61.
XiaL, WangM, LiH, et al.The effect of aberrant expression and genetic polymorphisms of Rad21 on cervical cancer biology. Cancer Med, 2018; 7(7):3393–3405; doi: 10.1002/cam4.1592
62.
YagerJD, DavidsonNE. Estrogen carcinogenesis in breast cancer. N Engl J Med, 2006; 354(3):270–282; doi: 10.1056/NEJMra050776
63.
YangPJ, HouMF, Ou-YangF, et al.Association of early-onset breast cancer with body mass index, menarche, and menopause in Taiwan. BMC Cancer, 2022; 22(1):259; doi: 10.1186/s12885-022-09361-2
64.
YanoK, ShiotaniB. Emerging strategies for cancer therapy by ATR inhibitors. Cancer Sci, 2023; 114(7):2709–2721; doi: 10.1111/cas.15845
65.
YapYS. Outcomes in breast cancer-does ethnicity matter?. ESMO Open, 2023; 8(3):101564; doi: 10.1016/j.esmoop.2023.101564
66.
YapYS, LuYS, TamuraK, et al.Insights into breast cancer in the east vs the west: A review. JAMA Oncol, 2019; 5(10):1489–1496; doi: 10.1001/jamaoncol.2019.0620
67.
YoshimuraA, ImotoI, IwataH. Functions of breast cancer predisposition genes: Implications for clinical management. Int J Mol Sci, 2022; 23(13):doi: 10.3390/ijms23137481
68.
ZhangY, ZhangL, LiR, et al.Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility. Ann Oncol, 2017; 28(7):1625–1630; doi: 10.1093/annonc/mdx161
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
